Idiotype-specific T cells in multiple myeloma: Targets for an immunotherapeutic intervention?

Medical Oncology

Volumn 13, Issue 1, 1996, Pages 1-7

  Yi, Qing ^a   Österborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

idiotype; M component; Multiple myeloma; T cells

Indexed keywords

GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOGLOBULIN IDIOTYPE; IMMUNOMODULATING AGENT;

ANTIGEN PRESENTATION; ARTICLE; CELL CLONE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0029816960     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988835     Document Type: Article

References (70)

1. Mellstedt, H., Holm, G. and Björkholm, M. (1984) Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications. Adv. Cancer Res. 41, 257-89.
2. Osgood, E.E. (1960) The survival time of patients with plasmacytic myeloma. Cancer Chemther. Rep. 9, 1-10.
3. Alexanian, R., Haut, A., Khan, A.U. et al. (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208, 1680-85.
4. Harousseau, J.-L., Attal, M., Divine, M. et al. (1995) Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma. Blood 85, 3077-85.
5. Gahrton, G., Tura, S., Ljungman, P. et al. (1991) Allogeneic bone marrow transplantation in multiple myeloma. N. Engl. J. Med. 325, 1267-73.
6. MacKenzie, M.R. and Lewis, J.P. (1985) Cytogenetic evidence that the malignant event in multiple myeloma occurs in a precursor lymphocyte. Cancer Genet. Cytogenet. 17, 13-20.
7. Berenson, J., Wong, R., Kim, K. et al. (1987) Evidence of peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood 70, 1550-3.
8. Billadeau, D., Quam, L., Thomas, W. et al. (1992) Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 80, 1818-24.
9. Österborg, A., Steinitz, M., Lewin, N. et al. (1991) Establishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy. Blood 78, 2642-9.
10. Bergui, L., Schena, M., Gaidano, G. et al. (1989) Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J. Exp. Med. 170, 613-8.
11. Takishita, M., Kosaka, M., Goto, T. et al. (1994) Cellular origin and extent of clonal involvement in multiple myeloma: genetic and phenotypic studies. Br. J. Haematol. 87, 735-42.
12. Billadeau, D., Ahmann, G., Greipp, P. et al. (1993) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J. Exp. Med. 178, 1023-31.
13. Bakkus, M.H., van Riet, I., Camp, B.V. et al. (1994) Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br. J. Haemtol. 87, 68-74.
14. Vescio, R.A., Cao, J., Hong, C.H. et al. (1995) Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but not intraclonal diversity. J. Immunol. 155, 2487-97.
15. Fearon, E.R. and Vogelstein, B. (1990) A genetic mode for colorectal tumorigenesis. Cell 61, 759-67.
16. Mellstedt, H., Killander, D. and Pettersson, D. (1977) Bone marrow kinetic studies on three patients with myelomatosis: indications for malignant proliferation within both the plasma cell and lymphoid cell compartments. Acta Med. Scand. 202, 413-7.
17. Chan, C.S., Wormsley, S.B., Pierce, L.E. et al. (1990) B-cell surface phenotypes of proliferating myeloma cells: target antigen for immunotherapy. Am. J. Hematol. 33, 101-9.
18. Pilarski, L.M. and Belch, A.R. (1994) Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 83, 724-36.
19. Corradini, P., Voena, C., Astolfi, M. et al. (1995) High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85, 1596-1602.
20. Österborg, A., Nilsson, B., Björkholm, M. et al. (1987) Blood clonal B cell excess at diagnosis in multiple myeloma. Relation to prognosis. Eur. J. Haematol. 38, 173-8.
21. Isaksson, E., Björkholm, M., Holm, G. et al. (1996) Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. Br. J. Haematol. 92, 71-6.
22. Lynch, R.G., Graff, R.J., Sirisinha, S. et al. (1972) Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69, 1540-4.
23. Stevenson, F.K., George, A.J.T. and Glennie, M.J. (1990) Anti-idiotypic therapy of leukemias and lymphomas. Chem. Immunol. 48, 126-66.
24. Jerne, N.K. (1974) Towards a network theory of the immune system. Ann. Immunol. (Inst. Pasteur), 125C, 373-89.
25. Lynch, R.G. (1987) Immunoglobulin-specific suppressor T cells. Adv. Immunol. 40, 135-51.
26. Mahony, J., Bose, A., Cowdrey, D. et al. (1981) A monoclonal antiidiotypic antibody to MOPC 315 IgA inhibits the growth of MOPC 315 myeloma cells in vitro. J. Immunol. 126, 113-7.
27. Germain, R.N. (1994) MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76, 287-99.
28. Bogen, B., Malissen, B. and Haas, W. (1986) Idiotype-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur. J. Immunol. 16, 1373-8.
29. Daley, M.J., Gebel, H.M. and Lynch, R.G. (1978) Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy. J. Immunol. 120, 1620-4.
30. Flood, P.M., Philipps, C., Taupier, M.A. et al. (1980) Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes. J. Immunol. 124, 424-30.
31. Hornung, R.L., Longo, D.L., Bowersox, O.C. et al. (1995) Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor. J. Natl Cancer Inst. 87, 1289-96.
32. Bergman, L., Mitrou, P.S., Kelker, W. et al. (1985) T-cell subsets in malignant lymphomas and monoclonal gammopathies. Scand. J. Haematol. 34, 170-6.
33. Mellstedt, H., Holm, G., Pettersson, D. et al. (1982) T cells in monoclonal gammopathies. Scand. J. Haematol. 29, 57-64.
34. San Miguel, J.F., Caballero, M.D. and Gonzalez, M. (1985) T-cell subpopulations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia. Am. J. Hematol. 20, 267-73.
35. Shapira, R., Froom, P., Kinarty, A. et al. (1989) Increase in the suppressor-inducer T cell subset in multiple myeloma and monoclonal gammopathy of undetermined significance. Br. J. Haematol. 71, 223-5.
36. + T cells in peripheral blood of multiple myeloma patients. J. Clin. Immunol. 8, 259-65.
37. Paglieroni, T. and MacKenzie, M.R. (1979) In vitro cytotoxic response to human myeloma plasma cells by peripheral blood leukocytes from patients with multiple myeloma and benign monoclonal gammopathy. Blood 54, 226-37.
38. Hoover, R.G., Hickman, S., Gebel, H.M. et al. (1981) Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma. J. Clin. Invest. 67, 308-11.
39. Massaia, M., Attisano, C., Peola, S. et al. (1993) Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood 82, 1787-97.
40. Massaia, M., Borrione, P., Attisano, C. et al. (1995) Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 85, 3679-87.
41. Janson, C.H., Grunewald, J., Österborg, A. et al. (1991) Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 77, 1776-80.
42. Moss, P.A.H., Gillespie, G., Frodsham, P. et al. (1994) Clonal populations of CD4 and CD8 T cells in patients with paraproteinaemia and myeloma. Blood 84 (suppl. 1), 177a (abstr.).
43. Farace, F., Orlanducci, F., Dietrich, P-Y. et al. (1994) T cell repertoire in patients with B chronic lymphocytic leukemia. J. Immunol. 153, 4281-90.
44. Sensi, M.L. and Parmiani, G. (1995) Analyses of TCR usage in human tumors: a new tool for assessing tumor specific immune responses. Immunol. Today 16, 588-95.
45. Hecht, T.T., Longo, D.L. and Matis, L.A. (1983) The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J. Immunol. 131, 1049-55.
46. Czerkinsky, C.C., Andersson, G., Ekre, H.P. et al. (1988) Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Meth. 110, 29-36.
47. Yi, Q., Bergenbrant, S., Österborg, A. et al. (1993) T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand. J. Immunol. 38, 529-34.
48. 2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol. Immunother. 34, 157-62.
49. Holm, G., Bergenbrant, S., Lefvert, A.K., Yi, Q. et al. (1991) Anti-idiotypic immunity as a potential regulator in myeloma and related diseases. Ann. NY Acad. Sci. 636, 178-83.
50. Österborg, A., Yi, Q., Bergenbrant, S. et al. (1995) Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br. J. Haematol. 89, 110-6.
51. Romagnani, S. (1991) Human TH1 and TH2 subsets: doubt no more. Immunol. Today 12, 256-7.
52. Yi, Q., Österborg, A., Bergenbrant, S. et al. (1995) Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86, 3043-9.
53. Lauritzsen, G.F. and Bogen, B. (1991) Idiotype-specific, major histocompatibility complex restricted T cells are of both Th1 and Th2 type. Scand. J. Immunol. 33, 647-56.
54. Lauritzsen, G.F., Weiss, S. and Bogen, B. (1993) Anti-tumor activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand. J. Immunol. 37, 77-85.
55. Clark, E.A. and Ledbetter, J.A. (1994) How B and T cells talk to each other. Nature 367, 425-8.
56. Hilbert, D.M., Shen, M-Y., Rapp, U.R. et al. (1995) T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc. Natl. Acad. Sci. USA 92, 649-53.
57. Paglieroni, T., Caggiano, V. and MacKenzie, M. (1992) Abnormalities in immune regulation precede the development of multiple myeloma. Am. J. Hematol. 40, 51-5.
58. Dianzani, U., Pileri, A., Boccadoro, M. et al. (1988) Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 72, 1064-8.
59. Bottomly, K. and Mosier, D.E. (1981) Antigen-specific helper T cells required for dominant idiotype expression are not H-2 restricted. J. Exp. Med. 154, 411-21.
60. Parra, C.C., Lima, M.S., Gazzinelli, G. et al. (1988) Immune responses during human Schistosomiasis Mansoni. XV. Anti-idiotypic T cells can recognize and respond to anti-SEA idiotypes directly. J. Immunol. 140, 2401-5.
61. Yamamoto, H., Araki, K., Bitoh, S. et al. (1987) Cytotoxic T lymphocyte done recognizing self idiotype: its regulatory role in antibody production. Eur. J. Immunol. 17, 719-22.
62. Yi, Q., Holm, G. and Lefvert, A.K. (1996) Idiotype-induced T cell stimulation requires antigen presentation in association with HLA-DR molecules. Clin. Exp. Immunol. 104, 359-650.
63. George, A.J.T., Folkard, S.G., Hamblin, T.J. et al. (1988) Idiotypic vaccination as a treatment for a B cell lymphoma. J. Immunol. 141, 2168-74.
64. Kwak, L.W., Campbell, M. and Levy, R. (1991) Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Cancer Detec. Prev. 15, 323-5.
65. Kwak, L.W., Campbell, M., Czerwinski, D.K. et al. (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209-15.
66. Raffeld, M., Necker, L., Longo, D.L. et al. (1985) Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma: Escape from detection by anti-idiotype. N. Engl. J. Med. 312, 1653-8.
67. Maloney, D.G., Brown, S., Czerwinski, D.K. et al. (1992) Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80, 1502-10.
68. Bakkus, M.H.C., Heirman, C., van Riet, I. et al. (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80, 2326-35.
69. Bergenbrant, S., Yi, Q., Österborg, A. et al. (1996) Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br. J. Haematol. 92, 840-6.
70. Kwak, L.W., Taub, D.D., Duffey, P.L. et al. (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345, 1016-20.